UCB |
Market Closed -
Other stock markets
|
After market 03:18:29 pm | |||
| 121.2 EUR | +1.00% |
|
121.5 | +0.25% |
| Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
| Sales 2024 * | 5.61B 5.98B | Sales 2025 * | 6.31B 6.71B | Capitalization | 22.77B 24.24B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 496M | Net income 2025 * | 880M 937M | EV / Sales 2024 * | 4.35 x |
| Net Debt 2024 * | 1.63B 1.73B | Net Debt 2025 * | 800M 852M | EV / Sales 2025 * | 3.74 x |
| P/E ratio 2024 * |
48.9
x | P/E ratio 2025 * |
24.8
x | Employees | 8,767 |
| Yield 2024 * |
1.17% | Yield 2025 * |
1.21% | Free-Float | 61.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on UCB
More press releases
More news
| 1 day | -0.96% | ||
| 1 week | -1.49% | ||
| Current month | +3.89% | ||
| 1 month | +9.74% | ||
| 3 months | +44.48% | ||
| 6 months | +64.02% | ||
| Current year | +50.63% |
1 week
117.75
121.10
1 month
107.30122.60
Current year
78.72122.60
1 year
65.40122.60
3 years
65.40122.60
5 years
60.18122.60
10 years
54.84122.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 11-05-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 20-06-30 |
| Chief Tech/Sci/R&D Officer | 63 | 17-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 16-04-27 | |
Dame Davies
BRD | Director/Board Member | 73 | 13-12-31 |
| Chief Executive Officer | 65 | 11-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.88% | 2 M€ | +5.72% | ||
| 0.72% | 14 M€ | +5.66% | - | |
| 0.72% | 5 M€ | +10.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 121.2 | +1.00% | 196 717 |
| 24-04-18 | 120 | +0.08% | 265,450 |
| 24-04-17 | 119.9 | +0.46% | 269,115 |
| 24-04-16 | 119.4 | -0.08% | 161,950 |
| 24-04-15 | 119.4 | -0.99% | 284,277 |
Real-time Euronext Bruxelles, April 19, 2024 at 05:10 am EDT
More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
120
EUR
Average target price
122.2
EUR
Spread / Average Target
+1.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.63% | 24.28B | |
| -5.99% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -4.27% | 8.07B | |
| +0.53% | 7.51B |
- Stock Market
- Equities
- UCB Stock
